GoodRx Holdings, Inc. (GDRX) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
GoodRx’s revenue went from $250M in fiscal 2018 to $797M in fiscal 2025, growth of about 18.0% a year.
Net income in fiscal 2025 was $30M, a net margin of 3.8%; the best year in this period was 2019 with $66M.
Over the twelve months to June 30, 2026, revenue was $785M and net income $16M.
Free cash flow was $164M in fiscal 2025 and positive in 8 of the 8 years shown.
The diluted share count rose 202% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $785M | $797M | $792M | $750M | $767M | $745M | $551M | $388M | $250M |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Operating income | $75M | $87M | $66M | -$27M | $2M | $13M | -$276M | $140M | $77M |
| Net income | $16M | $30M | $16M | -$9M | -$33M | -$25M | -$294M | $66M | $44M |
| EPS (diluted) | $0.04 | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 | $0.18 | $0.12 |
| R&D | $117M | $121M | $124M | $136M | $143M | $126M | $62M | $29M | $44M |
| Revenue growth | — | +0.6% | +5.6% | −2.1% | +2.8% | +35.4% | +41.9% | +55.6% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $202M | $168M | $184M | $138M | $147M | $179M | $131M | $83M | $45M |
| Capital spending | -$4M | -$4M | -$1M | -$1M | -$4M | -$5M | -$21M | -$1M | -$804000 |
| Free cash flow | $197M | $164M | $183M | $137M | $143M | $174M | $111M | $82M | $44M |
| Dividends paid | — | — | — | — | — | — | — | — | $1.3B |
| Buybacks | $85M | $216M | $159M | $104M | $102M | $0 | $0 | — | — |
| Stock-based pay | $69M | $77M | $99M | $105M | $120M | $160M | $397M | $4M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $262M | $448M | $672M | $757M | $941M | $969M | $26M | $35M |
| Debt | — | $550M | $552M | $711M | $725M | $714M | $719M | $711M | — |
| Equity | — | $616M | $725M | $762M | $815M | $832M | $711M | -$1.1B | -$1.2B |
| Total assets | — | $1.4B | $1.4B | $1.6B | $1.6B | $1.6B | $1.5B | $387M | — |
| Shares (diluted) | 348M | 357M | 392M | 410M | 413M | 410M | 275M | 231M | 118M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | 9.5% | 11.0% | 8.3% | -3.6% | 0.2% | 1.8% | -50.1% | 36.0% | 31.0% |
| Net margin | 2.1% | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% | 17.0% | 17.5% |
| FCF margin | 25.1% | 20.6% | 23.1% | 18.3% | 18.6% | 23.4% | 20.1% | 21.1% | 17.8% |
| ROIC | — | 4.0% | 2.7% | -1.5% | 0.1% | 0.7% | -18.6% | — | — |
| ROE | — | 4.9% | 2.3% | -1.2% | -4.0% | -3.0% | -41.3% | -6.1% | -3.8% |
Frequently asked questions
What is GoodRx’s annual revenue?
$797M in fiscal 2025 and $785M over the twelve months to June 30, 2026.
How much profit does GoodRx make?
Net income was $30M in fiscal 2025 (net margin 3.8%).
Is GoodRx’s revenue growing?
Yes: revenue rose 0.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.